Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 98 of 1,261
  1. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  2. US 12070510

    Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid

    REGENXBIO INC. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  3. US 12070628

    Low energy immune priming for treating cancer and metastasis

    Montefiore Medical Center Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  4. US 12071436

    Anti-parasitic compounds and uses thereof

    The Regents of the University of California Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  5. US 12071636

    Pasteurella multocida strains and vaccines having hyaC and nanP deletions

    The United States of America, as represented by the Secretary of Agriculture Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  6. US 12070444

    Modulation of molecular markers using S-equol

    The Board of Regents of the University of Texas System Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  7. US 12070509

    Nucleic acids and methods of treatment for cystic fibrosis

    ARCTURUS THERAPEUTICS, INC. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  8. US 12070594

    Biomedical electrode with anti-microbial properties

    COMPASS HEALTH BRANDS CORP. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  9. US 12071516

    Polymeric stabilizing formulations

    Nano Precision Medical, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  10. US 12071477

    Anti-folate receptor alpha antibody conjugated with hemiasterlins

    Sutro Biopharma, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  11. US 12071468

    Purification of Factor VIII subspecies

    Takeda Pharmaceutical Company Limited Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  12. US 12071413

    Azole derivatives as apelin receptor agonist

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  13. US 12070506

    Steroids and antibody-conjugates thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  14. US 12070472

    Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds

    The Board of Regents of the University of Texas System Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  15. US 12071434

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  16. US 12071414

    Apelin receptor agonists and methods of use thereof

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  17. US 12070443

    Methods of treating and preventing breast cancer with S-equol

    The Board of Regents of the University of Texas System Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  18. US 12072338

    Pharmaceutical peptides for the treatment of inflammatory diseases

    PROTAGONISTS LTD. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  19. US 12071438

    Crystal forms of an ALK2 inhibitor

    Keros Therapeutics, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  20. US 12071391

    Methods for making and using endoxifen

    ATOSSA THERAPEUTICS, INC. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  21. US 12071442

    Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists

    Nimbus Saturn, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  22. US 12071619

    SERPINA1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  23. US 12071411

    Inhibitors of HIF-2Ξ± and methods of use thereof

    Arcus Biosciences, Inc. Β· Granted Aug 27, 2024 Β· Expires Aug 22, 2044

    granted
  24. US 12068729

    Anti-factor XII/XIIa antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. Β· Granted Aug 20, 2024 Β· Expires Aug 15, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.